Japan's Ministry of Health, Labor and Welfare approved Shionogi new crown oral drug EUA
On November 22, Japan's Ministry of Health, Labor and Welfare approved Shionogi new crown oral drug EUA.
Previously, on September 28, Shionogi announced that the Phase III portion of a Phase II/III clinical trial of the 3CL protein inhibitor Ensitrelvir Fumaric Acid (S-217622) in Asia met the primary endpoint.
The results showed that, for the first time, ensitrelvir was shown to significantly reduce the time to remission of the five typical symptoms of Omicron compared to placebo. At the same time, ensitrelvir also showed a significant reduction in viral RNA load on day 4 (after the third dose).
This is the second 3CL drug after Pfizer paxlovid. The difference is that paxlovid needs to be used in combination with ritonavir. Enstirelvir alone can be effective.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-02
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
BioNTech’s Founders Turn the Page
-
India’s API Trade Balance Turns Positive
-
Novo Nordisk Faces a Compliance Test
-
Lilly Bets Bigger on China
Recommend Reading
-
Rising API Costs Threaten Drug Prices
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
Titan Technology Makes Bold Move with 55.85 Million Yuan Acquisition of UK Biochemical Firm ASL — What's Behind the Deal?
-
This Week's Styrene Market Weakens and Declines (4.20-4.24)
-
This week, the caustic soda price was weak in China (4.20-4.24)
-
Polyester Bottle Flakes Remain Highly Volatile This Week; Weekly Average Price Rises Compared to Previous Week
-
This Week's PVC Market in China: Bottoming Out with Low-level Fluctuations, Intensifying Supply and Demand Competition